We are live on ! Find out more
AAA

Affinity Asset Advisors Portfolio holdings

AUM $1.94B
1-Year Est. Return 374.45%
This Fund
S&P 500
This Quarter Est. Return
-5.74%
1 Year Est. Return
+374.45%
3 Year Est. Return
+1,279.72%
5 Year Est. Return
+2,528.28%
10 Year Est. Return
–
AUM
$625M
AUM Growth
+$350M
Cap. Flow
+$339M
Cap. Flow %
54.24%
Top 10 Hldgs %
74.87%
Holding
79
New
22
Increased
18
Reduced
8
Closed
20

Top Buys

Rank Stock Value
1
ASND icon
Ascendis Pharma A/S
ASND
+$13.9M
2
AZN icon
AstraZeneca
AZN
+$9.59M
3
NARI
Inari Medical, Inc. Common Stock
NARI
+$7.78M
4
NSTG
NanoString Technologies, Inc.
NSTG
+$5.91M
5
ESTA icon
Establishment Labs
ESTA
+$5.67M

Top Sells

Rank Stock Value
1
ARNA
Arena Pharmaceuticals Inc
ARNA
+$9.29M
2
BBIO icon
BridgeBio Pharma
BBIO
+$8.24M
3
CYTK icon
Cytokinetics
CYTK
+$6.63M
4
CERE
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
+$4.53M
5
ACRS icon
Aclaris Therapeutics
ACRS
+$4.09M

Sector Composition

Rank Sector Weight
1 Healthcare 34.14%
2 Financials 1.56%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IMTXW
51
DELISTED
Immatics N.V. Warrants
IMTXW
$328K 0.05%
187,204
-2,796
-1% -$6.43K
HYPR icon
52
Hyperfine
HYPR
$95.9M
$270K 0.04%
76,162
– –
BPMC
53
DELISTED
Blueprint Medicines
BPMC
$127K 0.02%
+1,988
New +$143K
RCOR.WS
54
DELISTED
Renovacor, Inc. Warrants, entitling the holder thereof to purchase one-half (1/2) of a share of common stock at a price of $11. 50 per whole share
RCOR.WS
$26K ﹤0.01%
75,000
– –
MSACW
55
DELISTED
Medicus Sciences Acquisition Corp. Warrant
MSACW
$14K ﹤0.01%
33,333
– –
ALDX icon
56
Aldeyra Therapeutics
ALDX
$104M
– –
-100,759
Closed -$403K
ARKG icon
57
CALL
ARK Genomic Revolution ETF
ARKG
$1.55B
– –
-25,000
Closed -$1.53M
BBIO icon
58
BridgeBio Pharma
BBIO
$16B
– –
-494,046
Closed -$8.24M
CRIS icon
59
CALL
Curis
CRIS
$8.97M
– –
-2,625
Closed -$5M
CVAC
60
CALL
DELISTED
CureVac
CVAC
– –
-50,000
Closed -$1.72M
CYTK icon
61
Cytokinetics
CYTK
$10.9B
– –
-145,552
Closed -$6.63M
INO icon
62
CALL
Inovio Pharmaceuticals
INO
$88.9M
– –
-16,667
Closed -$998K
IOVA icon
63
Iovance Biotherapeutics
IOVA
$2.24B
– –
-20,000
Closed -$382K
MRNA icon
64
PUT
Moderna
MRNA
$24.4B
– –
-30,000
Closed -$7.62M
NTLA icon
65
Intellia Therapeutics
NTLA
$1.56B
– –
-10,000
Closed -$1.18M
NVAX icon
66
PUT
Novavax
NVAX
$1.31B
– –
-50,000
Closed -$7.15M
PRCT icon
67
Procept Biorobotics
PRCT
$1.1B
– –
-100,000
Closed -$2.5M
RFL icon
68
PUT
Rafael Holdings
RFL
$112M
– –
-102,617
Closed -$516K
FLNA
69
PUT
Filana Therapeutics
FLNA
$49.3M
– –
-350,000
Closed -$15.3M
SEER icon
70
CALL
Seer Inc
SEER
$115M
– –
-50,000
Closed -$1.14M
SNDX icon
71
Syndax Pharmaceuticals
SNDX
$2.01B
– –
-175,000
Closed -$3.83M
ARYD
72
DELISTED
ARYA Sciences Acquisition Corp IV Class A Odinary Shares
ARYD
– –
-400,000
Closed -$3.97M
MRTX
73
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
– –
-20,000
Closed -$2.93M
GRNA
74
DELISTED
GreenLight Biosciences Holdings, PBC Common Stock
GRNA
– –
-300,000
Closed -$2.98M
ARNA
75
DELISTED
Arena Pharmaceuticals Inc
ARNA
– –
-100,000
Closed -$9.29M
1 2
3

Similar funds

FM
Foster & Motley Cincinnati, Ohio $1.94B AUM 21.65% 1-Year Est. Return
1SB
1ST Source Bank South Bend, Indiana $1.94B AUM 20.3% 1-Year Est. Return
HCL
Heard Capital LLC Chicago, Illinois $1.93B AUM 21.66% 1-Year Est. Return
OCM
Osterweis Capital Management San Francisco, California $1.94B AUM 20.77% 1-Year Est. Return
MWA
Midland Wealth Advisors Effingham, Illinois $1.94B AUM 14.31% 1-Year Est. Return
AF
Advisornet Financial Minnetonka, Minnesota $1.93B AUM 18.43% 1-Year Est. Return
NFG
Nations Financial Group Cedar Rapids, Iowa $1.94B AUM 25.76% 1-Year Est. Return
HC
Hamilton Capital Columbus, Ohio $1.93B AUM

Affinity Asset Advisors's Q1 2022 Portfolio in Review

As of Q1 2022, Affinity Asset Advisors held 79 positions worth $625M, up 127% from $275M the previous quarter. Its ten largest holdings account for 75% of the portfolio.

Affinity Asset Advisors deployed $339M of net new capital in Q1 2022, opening 22 new positions and adding to 18 existing holdings. Its largest new stake was Ascendis Pharma A/S: 120,000 shares worth $14.1M.

By sector, the portfolio is most concentrated in Healthcare at 34% of assets, down from 75% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Cerevel Therapeutics Holdings, Inc. Common Stock, an estimated $4.53M trimmed.

  • Affinity Asset Advisors's largest Q1 2022 buy was Ascendis Pharma A/S: 120,000 shares worth $14.1M.
  • Affinity Asset Advisors added most to Inari Medical, Inc. Common Stock in Q1 2022, an estimated $7.78M increase.
  • Affinity Asset Advisors's biggest Q1 2022 reduction was Cerevel Therapeutics Holdings, Inc. Common Stock, cutting an estimated $4.53M.
  • Affinity Asset Advisors fully exited Arena Pharmaceuticals Inc in Q1 2022, selling an estimated $9.29M.
  • Affinity Asset Advisors's ten largest holdings make up 75% of its $625M portfolio in Q1 2022.
  • Affinity Asset Advisors opened 22 new positions and closed 20 in Q1 2022.
  • Affinity Asset Advisors's portfolio value rose 127% quarter-over-quarter to $625M.

Based on Affinity Asset Advisors's 13F filing for Q1 2022, filed 13 May 2022.